Synergistic Analyte Monitoring System
Legal Citation
Summary of the Inventive Concept
A novel system integrating microneedle array-based continuous analyte monitoring devices with distinct technologies like AI, IoT, blockchain, and new materials to enhance fault detection, security, and predictive analytics.
Background and Problem Solved
The original patent addresses the need for continuous analyte monitoring, particularly for diabetic patients. However, it has limitations in detecting faults, ensuring data security, and predicting analyte levels. The new inventive concept solves these problems by incorporating synergistic combinations of technologies to create a more powerful and efficient system.
Detailed Description of the Inventive Concept
The system consists of a microneedle array-based sensor, an IoT-enabled communication module, a sensor data analytics module utilizing machine learning algorithms, and a blockchain-based health data storage system. The sensor data analytics module identifies anomalies in sensor data and transmits alerts to the user's mobile device. The blockchain-based system securely stores sensor data in a decentralized manner. Additionally, the system includes an artificial intelligence-powered predictive analytics module that generates predictions of future analyte levels based on machine learning algorithms. A secure authentication module utilizing biometric data ensures the security of the system.
Novelty and Inventive Step
The new inventive concept's novelty lies in the synergistic integration of distinct technologies, which provides a more comprehensive and efficient analyte monitoring system. The inventive step is the combination of machine learning algorithms, blockchain technology, and IoT-enabled communication modules with microneedle array-based sensors, resulting in a system that detects faults, ensures data security, and predicts analyte levels more effectively.
Alternative Embodiments and Variations
Alternative embodiments may include integrating the system with other wearable devices, utilizing different machine learning algorithms, or incorporating additional security measures. Variations may include using different types of sensors or data analytics modules, or applying the system to other health monitoring applications.
Potential Commercial Applications and Market
The synergistic analyte monitoring system has significant commercial potential in the healthcare industry, particularly in the fields of diabetes management, wearable devices, and health data analytics. The system's ability to provide more accurate and secure analyte monitoring data can improve patient outcomes and reduce healthcare costs.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61B5/685 |
| A | A61 | A61B5/14514 |
| A | A61 | A61B5/14532 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical device technology, specifically continuous analyte monitoring systems, focusing on electrochemical sensing, sensor fault detection, and data processing for chronic disease management
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or medical device designer with expertise in electrochemical sensors, signal processing, data analytics, and experience with wearable medical monitoring technologies
Obviousness Rationale
A PHOSITA would recognize that integrating advanced data processing, communication, and security technologies with the foundational microneedle array sensor represents a predictable technological evolution. The source patent's fault detection methodology naturally suggests expanding sensor capabilities through intelligent data analysis and communication strategies. The proposed variations represent standard engineering approaches to enhancing medical monitoring systems by leveraging contemporary technologies like machine learning, IoT, and blockchain.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,344 |
|---|---|
| Title | Fault detection for microneedle array based continuous analyte monitoring device |
| Assignee(s) | Biolinq Incorporated |